Clay Holmes

Contract Value Index (CVI)

The B Contract Value Index on Clay Holmes's deal stems from how WAR-level output tracks with AAV: at $12.7M annually over three years, Holmes earns starter money that aligns with the mid-tier production you'd expect from an established veteran pitcher, and his B performance grade reflects the reality that his stuff plays at an elite level when he takes the mound—the 2026 season shows 4 wins and 45 strikeouts across 9 games, solid counting numbers for a pitcher operating in a high-leverage role. The core tension in this CVI assessment isn't about what Holmes *can* do on the field; it's about durability in a starting pitcher role where innings pitched and health predictability anchor contract value. At $12.7M, he's priced like a reliable workhorse in a rotation, but the recurring hamstring issues and extended timeline into August have complicated that reliability calculus, shifting the burden of proof onto consistent availability rather than pure performance upside. At 33 and nine seasons into his career, Holmes represents the classic established-veteran bet—you're paying for a track record of high-leverage excellence, not projection, and that model only pencils out if durability concerns don't resurface. The Mets' recent roster additions across multiple positions signal organizational urgency to patch gaps elsewhere, which implicitly raises the stakes on Holmes's return timeline; the sentiment around his deal has deteriorated markedly as injury uncertainty persists, even though on-field production when healthy grades favorably. The three-year term carries meaningful risk if the hamstring proves chronic in a starting role, but the B-grade CVI reflects a fair-value contract for a proven arm whose actual stuff remains genuinely impressive—provided the training room updates begin trending toward consecutive healthy starts rather than another setback.

Performance Analysis